Your browser doesn't support javascript.
loading
Glucuronic acid is a novel source of pentosidine, associated with schizophrenia.
Toriumi, Kazuya; Iino, Kyoka; Ozawa, Azuna; Miyashita, Mitsuhiro; Yamasaki, Syudo; Suzuki, Kazuhiro; Sugawa, Hikari; Tabata, Koichi; Yamaguchi, Satoshi; Usami, Satoshi; Itokawa, Masanari; Nishida, Atsushi; Nagai, Ryoji; Kamiguchi, Hidenori; Arai, Makoto.
Afiliação
  • Toriumi K; Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
  • Iino K; Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
  • Ozawa A; Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
  • Miyashita M; Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan; Unit for Mental Health Promotion, Research Center for Social Science & Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-
  • Yamasaki S; Unit for Mental Health Promotion, Research Center for Social Science & Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
  • Suzuki K; Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan; Department of Community Mental Health, School of Medicine, Shinshu University, Nagano, 390-8621, Japan.
  • Sugawa H; Laboratory of Food and Regulation Biology, Graduate School of Bioscience, Tokai University, Kumamoto, 862-0970, Japan.
  • Tabata K; Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan; Department of Psychiatry and Behavioral Sciences, Tokyo Medical and Dental University Graduate School, Tokyo, 113-8510, Japan.
  • Yamaguchi S; Unit for Mental Health Promotion, Research Center for Social Science & Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
  • Usami S; Center for Research and Development on Transition from Secondary to Higher Education, The University of Tokyo, Tokyo, 113-0033, Japan.
  • Itokawa M; Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Tokyo, 156-0057, Japan.
  • Nishida A; Unit for Mental Health Promotion, Research Center for Social Science & Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
  • Nagai R; Laboratory of Food and Regulation Biology, Graduate School of Bioscience, Tokai University, Kumamoto, 862-0970, Japan.
  • Kamiguchi H; Takeda Pharmaceutical Company Ltd., Tokyo, 103-8668, Japan.
  • Arai M; Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan. Electronic address: arai-mk@igakuken.or.jp.
Redox Biol ; 67: 102876, 2023 11.
Article em En | MEDLINE | ID: mdl-37703666
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Lisina Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Redox Biol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Lisina Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Redox Biol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão